Mucopolysaccharidosis Type VII clinical trials at UCSF
2 research studies open to eligible people
Mucopolysaccharidosis type VII is a rare disorder that affects the body's sugar breakdown. UCSF is testing if giving enzymes to unborn babies is safe and possible. Another study is collecting data from patients to understand the disease's natural history.
In Utero Enzyme Replacement Therapy for Lysosomal Storage Diseases
open to eligible females ages 18-50
The investigators aims to determine the the maternal and fetal safety and feasibility of in utero fetal enzyme replacement therapy in fetuses with Lysosomal Storage Diseases.
San Francisco, California
Registry of Patients Diagnosed With Lysosomal Storage Diseases
open to eligible people ages up to 64 years
This is an international prospective and retrospective registry of patients with Lysosomal Storage Diseases (LSDs) to understand the natural history of the disease and the outcomes of fetal therapies, with the overall goal of improving the prenatal management of patients with LSDs.
San Francisco, California
Our lead scientists for Mucopolysaccharidosis Type VII research studies include Tippi Mackenzie.
Last updated: